| Q45861413 | A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach |
| Q28297096 | AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling |
| Q42468514 | Absence of the calcium-binding protein, S100A1, confers pulmonary hypertension in mice associated with endothelial dysfunction and apoptosis |
| Q79831895 | Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q35116100 | Altered myocardial calcium cycling and energetics in heart failure--a rational approach for disease treatment |
| Q36837270 | Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy |
| Q41775044 | Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals |
| Q42738033 | Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes |
| Q47828657 | Ca2+ leak-What is it? Why should we care? Can it be managed? |
| Q36544044 | Calcium homeostasis in human placenta: role of calcium-handling proteins |
| Q27026716 | Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies |
| Q37605483 | Calcium pumps in health and disease |
| Q38116830 | Calcium pumps: why so many? |
| Q28243737 | Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model |
| Q34409721 | Cardiac Gene Therapy |
| Q93370282 | Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond |
| Q37811189 | Cardiac gene therapy with SERCA2a: From bench to bedside |
| Q45883073 | Cardiac gene therapy: kick-starting calcium cycling in rats |
| Q37054935 | Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. |
| Q38506250 | Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology |
| Q27014770 | Cardiovascular gene therapy for myocardial infarction |
| Q41853464 | Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum |
| Q64930555 | Current Landscape of Heart Failure Gene Therapy. |
| Q36823697 | Current status of cardiovascular gene therapy |
| Q45866840 | Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart |
| Q37299072 | Designing heart performance by gene transfer. |
| Q30579578 | Differential effects of S100 proteins A2 and A6 on cardiac Ca(2+) cycling and contractile performance. |
| Q35225761 | Domestication of the cardiac mitochondrion for energy conversion |
| Q33995095 | Dot1a contains three nuclear localization signals and regulates the epithelial Na+ channel (ENaC) at multiple levels |
| Q48118483 | Enhanced Cardiac S100A1 Expression Improves Recovery from Global Ischemia-Reperfusion Injury |
| Q37630987 | Factors controlling the activity of the SERCA2a pump in the normal and failing heart. |
| Q48498411 | Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. |
| Q37001259 | Functions of S100 proteins. |
| Q38025012 | Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function |
| Q46181261 | Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the beta-adrenergic and renin-angiotensin systems |
| Q30427066 | Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications |
| Q26799437 | Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation |
| Q45857145 | Gene therapy for diabetic cardiomyopathy: a new approach for a difficult problem |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q83556143 | Gene therapy for heart failure |
| Q38073152 | Gene therapy for heart failure: where do we stand? |
| Q40014132 | Gene therapy for myocardial infarction-associated congestive heart failure: how far have we got? |
| Q36944623 | Gene therapy in heart failure |
| Q36786243 | Gene therapy in the treatment of heart failure |
| Q37310450 | Gene therapy to treat cardiovascular disease |
| Q41471609 | In-depth proteomic profiling of left ventricular tissues in human end-stage dilated cardiomyopathy |
| Q37071624 | Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive rats |
| Q36502630 | Integration of calcium with the signaling network in cardiac myocytes. |
| Q42450906 | Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction |
| Q46964433 | Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer |
| Q27012758 | Mechanisms of altered Ca²⁺ handling in heart failure |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q36480080 | Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy |
| Q37643467 | Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart. |
| Q26785883 | Multifaceted role of β-arrestins in inflammation and disease |
| Q88956893 | Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology |
| Q37176440 | Myocardial repair: from salvage to tissue reconstruction |
| Q30852031 | Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression |
| Q33906288 | Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes |
| Q36301726 | Oxidative stress in myocardial ischaemia reperfusion injury: a renewed focus on a long-standing area of heart research |
| Q41981837 | PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity |
| Q34776099 | Parvalbumin isoforms for enhancing cardiac diastolic function |
| Q38718829 | Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review. |
| Q37254944 | Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure |
| Q36497159 | Potential of gene therapy as a treatment for heart failure |
| Q45873132 | Recent findings into the potential of gene therapy to reverse heart failure |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q37964927 | Reverse remodeling in heart failure--mechanisms and therapeutic opportunities |
| Q37799093 | Ryanodine receptor assembly: A novel systems biology approach to 3D mapping |
| Q49497885 | S100 Proteins As an Important Regulator of Macrophage Inflammation. |
| Q36756998 | S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction. |
| Q37117354 | S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex |
| Q27651297 | S100A1 and Calmodulin Compete for the Same Binding Site on Ryanodine Receptor |
| Q28243947 | S100A1 and calmodulin regulation of ryanodine receptor in striated muscle |
| Q28261526 | S100A1 binds to the calmodulin-binding site of ryanodine receptor and modulates skeletal muscle excitation-contraction coupling |
| Q28291290 | S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials |
| Q28272699 | S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction |
| Q28245847 | S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes |
| Q28249115 | S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy |
| Q28240412 | S100A1 in human heart failure: lack of recovery following left ventricular assist device support |
| Q28240188 | S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4 |
| Q37082922 | S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats |
| Q28263662 | S100A1: Structure, Function, and Therapeutic Potential |
| Q26827725 | S100A1: a major player in cardiovascular performance |
| Q28288362 | S100A1: a multifaceted therapeutic target in cardiovascular disease |
| Q36801998 | S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance |
| Q33757903 | S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function |
| Q39247295 | S100A6 protein: functional roles |
| Q46330392 | SERCA control of cell death and survival |
| Q37676218 | Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure |
| Q34470451 | Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis |
| Q28259868 | Targeting S100A1 in heart failure |
| Q38248594 | The S100 protein family and its application in cardiac diseases. |
| Q28243220 | The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy |
| Q30577637 | The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition. |
| Q41890749 | Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model |
| Q89620118 | Unbalance Between Sarcoplasmic Reticulum Ca2 + Uptake and Release: A First Step Toward Ca2 + Triggered Arrhythmias and Cardiac Damage |
| Q48234052 | X-ray crystal structure of human calcium-bound S100A1. |
| Q64064280 | mA-mRNA methylation regulates cardiac gene expression and cellular growth |